Inactive Instrument

Breathtec Biomedical Inc Stock Deutsche Boerse AG

Equities

Biotechnology & Medical Research

Sales 2022 - Sales 2023 - Capitalization 2.6M 2.43M
Net income 2022 -6M -5.61M Net income 2023 -6M -5.61M EV / Sales 2022 -
Net cash position 2022 1.41M 1.32M Net cash position 2023 125K 117K EV / Sales 2023 -
P/E ratio 2022
-1.55 x
P/E ratio 2023
-0.37 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 79.39%
More Fundamentals * Assessed data
Dynamic Chart
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.017 million in funding CI
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset CI
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company MT
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc. CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis CI
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis MT
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023 CI
Algernon Pharmaceuticals Increased Private Placement MT
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.28 million in funding CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast MT
More news
Managers TitleAgeSince
Chief Executive Officer 59 18-02-28
Director of Finance/CFO 45 21-11-30
Chief Operating Officer 41 21-02-28
Members of the board TitleAgeSince
Chairman 79 21-09-07
Chief Executive Officer 59 18-02-28
Director/Board Member 52 21-09-21
More insiders
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
Calendar
More about the company